Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma

被引：9
|
作者：
Richter, Joshua R. [1 ]
Bilotti, Elizabeth [1 ]
McBride, Laura [1 ]
Schmidt, Linda [1 ]
Gao, Zhijie [2 ]
Tufail, Madiha [2 ]
Anand, Palka [1 ]
McNeill, Ann [1 ]
Bednarz, Urszula [1 ]
Graef, Thorsten [3 ]
Vesole, David H. [1 ]
Siegel, David S. [1 ]
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Univ Med & Dent NJ, Newark, NJ USA
[3] Merck Res Labs, Upper Gwynedd, PA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3986.3986
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1706 / 1706
页数：1
相关论文
共 50 条
  • [11] A PHASE I STUDY OF VORINOSTAT, LENALIDOMIDE, AND DEXAMETHASONE FOR RELAPSED AND REFRACTORY MULTPLE MYELOMA
    Richardson, P.
    Weber, D.
    Mitsiades, C.
    Dimopoulos, M.
    Harousseau, J. L.
    Howe, J.
    Graef, T.
    Gause, C.
    Byrne, C.
    Anderson, K.
    Siegel, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 155 - 156
  • [12] A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Siegel, David
    Weber, Donna
    Mitsiades, Constantine S.
    Rizvi, Syed
    Garcia-Vargas, Jose
    Howe, Jason
    Reiser, David
    Anderson, Kenneth C.
    Richardson, Paul
    BLOOD, 2008, 112 (11) : 1270 - 1270
  • [13] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [14] Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
    Palumbo, Antonio
    Dimopoulos, Meletios
    San Miguel, Jesus
    Harousseau, Jean-Luc
    Attal, Michel
    Hussein, Mohamad
    Knop, Stefan
    Ludwig, Heinz
    von Lilienfeld-Toal, Marie
    Sonneveld, Pieter
    BLOOD REVIEWS, 2009, 23 (02) : 87 - 93
  • [15] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Pareto, A. E.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S116 - S117
  • [16] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [17] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Belch, Andrew
    White, Darrell
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Sutherland, Heather J.
    Lalancette, Marc
    Magen, Hila
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, H. Miles
    Cochrane, Tara
    Oriol, Albert
    Bahlis, Nizar J.
    Chari, Ajai
    O'Rourke, Lisa
    Wu, Kaida
    Schecter, Jordan M.
    Casneuf, Tineke
    Chiu, Christopher
    Soong, David
    Sasser, A. Kate
    Khokhar, Nushmia Z.
    Avet-Loiseau, Herve
    Usmani, Saad Z.
    HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
  • [18] Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Maisnar, Vladimir
    Hajek, Roman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E271 - E272
  • [19] Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
    M A Dimopoulos
    A K Stewart
    T Masszi
    I Špička
    A Oriol
    R Hájek
    L Rosiñol
    D Siegel
    G G Mihaylov
    V Goranova-Marinova
    P Rajnics
    A Suvorov
    R Niesvizky
    A Jakubowiak
    J San-Miguel
    H Ludwig
    S Ro
    S Aggarwal
    P Moreau
    A Palumbo
    Blood Cancer Journal, 2017, 7 : e554 - e554
  • [20] A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
    Vesole, David H.
    Siegel, David Samuel DiCapua
    Richter, Joshua Ryan
    McNeill, Ann
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    McBride, Laura
    Raucci, Laura
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Smith, Judith
    Mato, Anthony R.
    Bilotti, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345